sodium acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4203 127-09-3

Description:

MoleculeDescription

Synonyms:

  • sodium acetate
  • anhydrous sodium acetate
  • acetic acid, sodium salt
  • sodium acetate anhydrous
The trihydrate sodium salt of acetic acid, which is used as a source of sodium ions in solutions for dialysis and as a systemic and urinary alkalizer, diuretic, and expectorant.
  • Molecular weight: 82.03
  • Formula: C2H3NaO2
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 4, 1983 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic anterior segment syndrome 518.37 66.46 69 463 1702 63486788
Endophthalmitis 227.57 66.46 37 495 3555 63484935
Post procedural complication 84.33 66.46 21 511 17053 63471437
Anterior chamber inflammation 72.12 66.46 10 522 317 63488173
Foetal growth restriction 67.30 66.46 15 517 7538 63480952

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic anterior segment syndrome 449.81 43.79 61 391 1108 34955371
Endophthalmitis 139.94 43.79 26 426 3482 34952997
Post procedural complication 78.82 43.79 20 432 11368 34945111
Cataract operation complication 74.58 43.79 10 442 156 34956323
Keratitis 52.92 43.79 10 442 1441 34955038

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic anterior segment syndrome 832.93 38.05 114 756 2650 79740868
Endophthalmitis 333.68 38.05 58 812 6370 79737148
Post procedural complication 137.55 38.05 35 835 23794 79719724
Cataract operation complication 128.55 38.05 17 853 284 79743234
Anterior chamber disorder 51.02 38.05 7 863 155 79743363
Keratitis 49.09 38.05 11 859 4311 79739207
Corneal oedema 42.84 38.05 9 861 2611 79740907
Intraocular pressure increased 40.83 38.05 11 859 9194 79734324
Corneal disorder 38.21 38.05 8 862 2283 79741235

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B05XA08 BLOOD AND BLOOD FORMING ORGANS
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
I.V. SOLUTION ADDITIVES
Electrolyte solutions

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Anuria contraindication 2472002 DOID:2983
Classical phenylketonuria contraindication 7573000
Poisoning by digitalis glycoside contraindication 12876009
Hyperkalemia contraindication 14140009
Complete atrioventricular block contraindication 27885002
Sarcoidosis contraindication 31541009 DOID:11335
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Heart disease contraindication 56265001 DOID:114
Congenital myotonia, autosomal dominant form contraindication 57938005
Acute nephropathy contraindication 58574008
Hypercalcemia contraindication 66931009 DOID:12678
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Hyperchloremia contraindication 74450001
Third degree burn injury contraindication 80247002
Oliguria contraindication 83128009
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Hyporeninemic hypoaldosteronism contraindication 236464008
Familial hyperkalemic periodic paralysis contraindication 304737009 DOID:14451
Azotemia contraindication 445009001
Severe dehydration contraindication 450316000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Carbonic anhydrase 1 Enzyme Ki 4.97 CHEMBL
Carbonic anhydrase Enzyme Ki 4.44 CHEMBL

External reference:

IDSource
4017442 VUID
N0000145830 NUI
4017442 VANDF
4018697 VANDF
C0142785 UMLSCUI
CHEBI:32954 CHEBI
CHEMBL1354 ChEMBL_ID
D019346 MESH_DESCRIPTOR_UI
DB09395 DRUGBANK_ID
4550K0SC9B UNII
517045 PUBCHEM_CID
267453 RXNORM
1707 MMSL
5468 MMSL
72037 MMSL
NOCODE MMSL
d00471 MMSL
000744 NDDF
000756 NDDF
6131-90-4 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
BSS HUMAN PRESCRIPTION DRUG LABEL 6 0065-0795 SOLUTION 3.90 mg OPHTHALMIC NDA 9 sections
BSS HUMAN PRESCRIPTION DRUG LABEL 6 0065-0795 SOLUTION 3.90 mg OPHTHALMIC NDA 9 sections
BSS HUMAN PRESCRIPTION DRUG LABEL 6 0065-0795 SOLUTION 3.90 mg OPHTHALMIC NDA 9 sections
BSS HUMAN PRESCRIPTION DRUG LABEL 6 0065-0795 SOLUTION 3.90 mg OPHTHALMIC NDA 9 sections
BSS HUMAN PRESCRIPTION DRUG LABEL 6 0065-1795 SOLUTION 3.90 mg OPHTHALMIC NDA 9 sections
BSS HUMAN PRESCRIPTION DRUG LABEL 6 0065-1795 SOLUTION 3.90 mg OPHTHALMIC NDA 9 sections
ProcalAmine HUMAN PRESCRIPTION DRUG LABEL 22 0264-1915 INJECTION 0.20 g INTRAVENOUS NDA 24 sections
ProcalAmine HUMAN PRESCRIPTION DRUG LABEL 22 0264-1915 INJECTION 0.20 g INTRAVENOUS NDA 24 sections
HyperlyteCR HUMAN PRESCRIPTION DRUG LABEL 5 0264-1943 INJECTION, SOLUTION, CONCENTRATE 0.68 g INTRAVENOUS UNAPPROVED DRUG OTHER 18 sections
HyperlyteCR HUMAN PRESCRIPTION DRUG LABEL 5 0264-1943 INJECTION, SOLUTION, CONCENTRATE 0.68 g INTRAVENOUS UNAPPROVED DRUG OTHER 18 sections
Balanced Salt HUMAN PRESCRIPTION DRUG LABEL 6 0264-1945 SOLUTION 3.90 mg IRRIGATION ANDA 11 sections
Physiolyte HUMAN PRESCRIPTION DRUG LABEL 5 0264-2205 IRRIGANT 0.37 g IRRIGATION NDA 20 sections
Physiolyte HUMAN PRESCRIPTION DRUG LABEL 5 0264-2205 IRRIGANT 0.37 g IRRIGATION NDA 20 sections
Physiolyte HUMAN PRESCRIPTION DRUG LABEL 5 0264-2205 IRRIGANT 0.37 g IRRIGATION NDA 20 sections
Physiolyte HUMAN PRESCRIPTION DRUG LABEL 5 0264-2205 IRRIGANT 0.37 g IRRIGATION NDA 20 sections
Balanced Salt HUMAN PRESCRIPTION DRUG LABEL 6 0264-2514 SOLUTION 3.90 mg IRRIGATION ANDA 11 sections
Isolyte S HUMAN PRESCRIPTION DRUG LABEL 5 0264-7703 INJECTION, SOLUTION 0.37 g INTRAVENOUS NDA 19 sections
Isolyte S HUMAN PRESCRIPTION DRUG LABEL 5 0264-7703 INJECTION, SOLUTION 0.37 g INTRAVENOUS NDA 19 sections
Isolyte S pH 7.4 HUMAN PRESCRIPTION DRUG LABEL 7 0264-7707 INJECTION, SOLUTION 0.37 g INTRAVENOUS NDA 24 sections
Isolyte S pH 7.4 HUMAN PRESCRIPTION DRUG LABEL 7 0264-7707 INJECTION, SOLUTION 0.37 g INTRAVENOUS NDA 24 sections
Isolyte S pH 7.4 HUMAN PRESCRIPTION DRUG LABEL 7 0264-7707 INJECTION, SOLUTION 0.37 g INTRAVENOUS NDA 24 sections
Isolyte S pH 7.4 HUMAN PRESCRIPTION DRUG LABEL 7 0264-7707 INJECTION, SOLUTION 0.37 g INTRAVENOUS NDA 24 sections
Isolyte P in Dextrose HUMAN PRESCRIPTION DRUG LABEL 5 0264-7730 INJECTION, SOLUTION 0.32 g INTRAVENOUS NDA 23 sections
Isolyte P in Dextrose HUMAN PRESCRIPTION DRUG LABEL 5 0264-7730 INJECTION, SOLUTION 0.32 g INTRAVENOUS NDA 23 sections
Isolyte P in Dextrose HUMAN PRESCRIPTION DRUG LABEL 5 0264-7730 INJECTION, SOLUTION 0.32 g INTRAVENOUS NDA 23 sections
Isolyte P in Dextrose HUMAN PRESCRIPTION DRUG LABEL 5 0264-7730 INJECTION, SOLUTION 0.32 g INTRAVENOUS NDA 23 sections
Plasma-Lyte 148 HUMAN PRESCRIPTION DRUG LABEL 5 0338-0179 INJECTION, SOLUTION 368 mg INTRAVENOUS NDA 20 sections
Plasma-Lyte 148 HUMAN PRESCRIPTION DRUG LABEL 5 0338-0179 INJECTION, SOLUTION 368 mg INTRAVENOUS NDA 20 sections
Plasma-Lyte 148 HUMAN PRESCRIPTION DRUG LABEL 5 0338-0179 INJECTION, SOLUTION 368 mg INTRAVENOUS NDA 20 sections
Plasma-Lyte 148 HUMAN PRESCRIPTION DRUG LABEL 5 0338-0179 INJECTION, SOLUTION 368 mg INTRAVENOUS NDA 20 sections